Guard Therapeutics International AB (publ) (GUARD.ST)

SEK 18.8

(2.73%)

Market Cap (In SEK)

231.14 Million

Revenue (In SEK)

-

Net Income (In SEK)

-113.32 Million

Avg. Volume

4241.00

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16.0-41.0
PE
-
EPS
-
Beta Value
0.048
ISIN
SE0021181559
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Tobias Larsson Agervald
Employee Count
-
Website
https://guardtherapeutics.com
Ipo Date
2013-04-03
Details
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.